Search the Newsreel

Nektar Therapeutics Q2 Results: Earnings date set for Aug 13

Nektar Therapeutics (Nasdaq: NKTR) is scheduled to release its second-quarter 2026 financial results on August 13, 2026, after the U.S. markets close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results, the company's financial health, and advancements …

Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis

Nektar Therapeutics (NKTR) has a current financial score of 6.40, placing it 254th out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently reported a quarterly revenue of $10.86 million, a 3.83% year-over-year …

Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Nektar Therapeutics (NKTR), highlighting its current valuation score of 7.54, which ranks 213 out of 386 in its industry. It details the company's current P/E ratio of -9.01, noting its position relative to recent highs and lows. …

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Nektar Therapeutics (NKTR) has initiated Phase 3 trials for rezpegaldesleukin in atopic dermatitis, a move that follows significant one-year stock growth but also a recent pullback. Despite a narrative suggesting a 54% undervaluation based on future revenue potential, its current P/S ratio signals high …

Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Nektar Therapeutics' (NKTR) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also includes institutional shareholding data over several quarters and recent shareholder activity, highlighting changes in holdings by various investment …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing by its officers and/or directors. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …

Krakatoa Resources Ltd. Revenue Breakdown – ASX:KTA

Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Nektar Therapeutics (NKTR), noting a lack of detailed financial disclosures for recent fiscal years. It indicates that all reported revenue, totaling $55.23 million, comes from the "Rest of world" region, with no disclosed revenue from the United …

How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials

Nektar Therapeutics has initiated global Phase 3 trials (ZENITH AD-1 and AD-2) for rezpegaldesleukin in moderate-to-severe atopic dermatitis, building on positive Phase 2b data and FDA Fast Track status. This move positions the T-reg–targeting biologic as a central focus for Nektar's autoimmune franchise but …

Nektar Therapeutics (NKTR) Institutional Confidence

The article provides an overview of Nektar Therapeutics' (NKTR) institutional confidence score, which stands at 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding proportion is 61.39%, a 16.36% decline quarter-over-quarter. James Simons is the largest institutional shareholder, with other major …

Okta (OKTA) Draws Fresh Analyst Support, Is It Fully Priced?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Analyst sentiment toward Okta (OKTA) has recently turned more favorable, with many brokerage firms rating the stock as a Buy or Strong Buy, …

Nektar Therapeutics (NKTR) awards 16,500 stock options to Chief R&D Officer

Nektar Therapeutics has granted Chief R&D Officer Jonathan Zalevsky 16,500 stock options with an exercise price of $15.1500 per share, expiring December 12, 2032. These options, issued under the 2017 Amended and Restated Performance Incentive Plan, are subject to both performance-based and time-based vesting. …

Okta, Inc. Revenue Breakdown – NASDAQ:OKTA

Form 4 Nektar Therapeutics For: 24 July By Investing.com

This article reports on a Form 4 filing for Nektar Therapeutics (NKTR) on July 24, indicating insider transactions. The brief piece includes the stock's performance on the day and is framed within a typical financial news portal layout with various market data and related …

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics announced the grant of non-qualified stock options to 23 newly-hired employees under its 2025 Inducement Plan, as permitted by Nasdaq Listing Rule 5635(c)(4). These options cover 36,000 shares of common stock at an exercise price of $64.84, vesting over four years. The …

Wall Street Analysts See Okta (OKTA) as a Buy: Should You Invest?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Nektar Therapeutics Initiated at Buy by Canaccord Genuity

Canaccord Genuity has initiated coverage on Nektar Therapeutics with a "Buy" rating. This indicates an optimistic outlook from the investment firm regarding the pharmaceutical company's future stock performance. Further details regarding specific price targets or reasons for the rating were not provided in this …

Here's Why Okta (OKTA) is a Great Momentum Stock to Buy

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Nektar Therapeutics (NKTR) announced the initiation of phase III clinical trials (ZENITH AD-1 and ZENITH AD-2) for its drug candidate, rezpegaldesleukin (rezpeg), to treat moderate-to-severe atopic dermatitis. The company's shares rose following the news, and rezpeg is also being developed for other autoimmune diseases …

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR) securities. The investigation focuses on whether Nektar and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before February 26, 2025, and still hold …

Is Okta’s (OKTA) AI Security Buzz Enough To Offset Slowing Growth Concerns?

Okta (OKTA) Stock Dips While Market Gains: Key Facts

Okta (OKTA) ended the recent trading session at $141.71, demonstrating a -4.51% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.89%. Meanwhile, the Dow gained 0.74%, and the Nasdaq, a tech-heavy index, added 1.29%. Shares of …

Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD

Nektar Therapeutics has launched its Phase 3 ZENITH AD program for rezpegaldesleukin, aimed at treating moderate-to-severe atopic dermatitis in patients aged 12 and older. The program includes three global trials, with ZENITH AD-1 and ZENITH AD-2 focusing on treatment-naive patients, and ZENITH AD-3 on …

Okta, Inc. (OKTA) Is a Trending Stock: Facts to Know Before Betting on It

Okta (OKTA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this cloud identity …

Wall Street Just Supersized Its Price Targets on Okta and Fortinet. Are Cybersecurity Stocks a Must-Own in 2026?

Quick Read Wells Fargo raised Okta's price target 50% to $150 and Fortinet's 71% to $120, keeping their ratings unchanged, as valuations rather than fundamentals remain the constraint. Palo Alto Networks and CrowdStrike share the same AI-driven demand surge, with shares up 95% and …

Okta’s 96.6% quarter leaves the stock 4.9% below its high, but participation is still ordinary

The identity-software stock sharply outperformed a weak Technology week, with the Trend Signal active and Relative Strength improving, though volume stayed below its 13-week average.

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing. The firm is encouraging shareholders who purchased NKTR securities before February 26, 2025, and still hold them, to join their securities investigation. The firm operates on …

Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR

This article displays financial data for Nektar Therapeutics (BMV:NKTR), specifically its Enterprise Value to EBIT forward. It appears to be a financial snapshot from TradingView, showing the absence of trades and outlining the company's financial overview within the health technology and pharmaceutical sectors. The …

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run

Nektar Therapeutics (NKTR) has seen a significant 7x return over the last three years but is currently screening as overvalued according to Simply Wall St's analysis. The company's P/S ratio of 41.5x is considerably higher than the industry average and its estimated fair P/S …

Price to sales forward of Nektar Therapeutics – BMV:NKTR

This article provides financial information for Nektar Therapeutics (NKTR) on the Mexican Stock Exchange, focusing on its price-to-sales forward metric. It highlights that the market is closed with no recent trades. The content is primarily a data page from TradingView, offering an overview of …

ETFs Investing in Nektar Therapeutics Stocks

This article provides a comprehensive list of ETFs that hold Nektar Therapeutics (NKTR) stocks, detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs listed predominantly focus on small-cap, extended market, or healthcare sectors, …

Okta Inc (OKTA) pullback meets an active weekly trend

The identity-software stock is easing after a sharp multiweek advance, making the next signals more about confirmation than fresh momentum.

Krakatoa Resources Lists 400 Million New Shares at AUD 0.004 Each

Okta Inc (OKTA) more than doubles over 12 weeks as weekly trend stays active

The identity-software stock finished at $141.42, with Market Dynamics confirming the move while turnover stayed below its recent norm.

Okta Inc (OKTA) extends triple-digit twelve-week surge

The identity-management software stock’s weekly trend remains active, though lighter turnover keeps the evidence from being one-sided.

Krakatoa Resources (ASX:KTA) Advances 2026 Work Program With Latest Capital Raise